Zacks Investment Research
27 Mar 2026, 17:11 UTC · 25w ago
Verdict
Headline leans bullish. We score KOD +1.00 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish
Kodiak Sciences' phase III GLOW2 study for Zenkuda (tarcocimab tedromer) met its primary endpoint with high statistical significance, showing 62.5% of patients achieved a >2-step improvement in DRSS versus 3.3% for sham.
More positive than 99% of claims this week
Zenkuda reduced the risk of developing sight-threatening complications, such as progression to PDR or center-involving DME, by 85% compared to the control group.
So whatHigh efficacy in preventing severe complications strengthens the drug's competitive positioning and potential market share in the diabetic retinopathy space.
Continue reading
5 related stories
More positive than 98% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 92% of claims this week
The GLOW2 study demonstrated that Zenkuda's efficacy remained consistent regardless of whether patients were using GLP-1 therapies.
More positive than 77% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
Shares surged 75% following positive top-line results from a phase III clinical study for Zenkuda.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
45m ago
−21.4%
Price is moving against the score
$31.26 vs $39.76 close before publication (Mar 26) · not market-adjusted
KOD chart →
